Becton, Dickinson and Company $BDX Holdings Lifted by Sector Gamma AS

Sector Gamma AS grew its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 11.1% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 108,829 shares of the medical instruments supplier’s stock after buying an additional 10,829 shares during the quarter. Becton, Dickinson and Company accounts for approximately 5.1% of Sector Gamma AS’s investment portfolio, making the stock its 5th biggest holding. Sector Gamma AS’s holdings in Becton, Dickinson and Company were worth $20,370,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. raised its stake in Becton, Dickinson and Company by 15.4% in the 2nd quarter. Vanguard Group Inc. now owns 32,308,749 shares of the medical instruments supplier’s stock valued at $5,565,182,000 after acquiring an additional 4,305,947 shares during the period. Massachusetts Financial Services Co. MA boosted its position in shares of Becton, Dickinson and Company by 7.5% in the third quarter. Massachusetts Financial Services Co. MA now owns 9,150,584 shares of the medical instruments supplier’s stock valued at $1,712,715,000 after acquiring an additional 636,138 shares during the period. First Eagle Investment Management LLC lifted its stake in Becton, Dickinson and Company by 59.2% in the 2nd quarter. First Eagle Investment Management LLC now owns 8,786,190 shares of the medical instruments supplier’s stock worth $1,513,421,000 after purchasing an additional 3,268,478 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Becton, Dickinson and Company by 3.8% during the 2nd quarter. Geode Capital Management LLC now owns 6,723,702 shares of the medical instruments supplier’s stock valued at $1,153,157,000 after purchasing an additional 244,199 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Becton, Dickinson and Company in the second quarter worth $653,377,000. 86.97% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently commented on BDX. Morgan Stanley boosted their target price on Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 2nd. Stifel Nicolaus upped their price objective on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Jefferies Financial Group boosted their price target on shares of Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a “buy” rating in a research note on Wednesday, December 10th. Finally, Royal Bank Of Canada raised their price objective on shares of Becton, Dickinson and Company from $202.00 to $210.00 and gave the company a “sector perform” rating in a research report on Wednesday, December 17th. Four equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $207.64.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,610 shares of the firm’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the sale, the executive vice president directly owned 12,095 shares of the company’s stock, valued at $2,509,228.70. This trade represents a 11.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Bertram L. Scott sold 217 shares of the company’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $176.58, for a total value of $38,317.86. Following the transaction, the director directly owned 35,816 shares of the company’s stock, valued at $6,324,389.28. The trade was a 0.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 2,662 shares of company stock worth $535,246. 0.40% of the stock is owned by insiders.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $201.84 on Friday. The company has a 50-day simple moving average of $197.40 and a two-hundred day simple moving average of $190.42. Becton, Dickinson and Company has a 12-month low of $162.29 and a 12-month high of $251.99. The firm has a market cap of $57.51 billion, a price-to-earnings ratio of 34.62, a PEG ratio of 2.23 and a beta of 0.23. The company has a quick ratio of 0.64, a current ratio of 1.11 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $3.96 EPS for the quarter, topping the consensus estimate of $3.92 by $0.04. The firm had revenue of $5.89 billion for the quarter, compared to the consensus estimate of $5.91 billion. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The company’s quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.81 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. On average, equities analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, December 31st. Stockholders of record on Monday, December 8th were issued a $1.05 dividend. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 annualized dividend and a dividend yield of 2.1%. The ex-dividend date was Monday, December 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 72.04%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.